Ekso Bionics Holdings Inc (NAS:EKSO)

Q4 2024 Ekso Bionics Holdings Inc Earnings Call Transcript

Mar 3, 2025 / 09:30 PM GMT

Release Date Price: $7.23 (-8.14%)

Transcript 10-K8-K

Key Points

Positve

Ekso Bionics Holdings Inc (EKSO) achieved record revenue of $5.1 million in Q4 2024, marking a 5% increase from the same period in 2023.
Gross profit for Q4 2024 was $2.7 million, with a gross margin of approximately 53%, up from 49% in Q4 2023, due to cost savings in supply chain and service costs.
Operating expenses decreased by 15% in Q4 2024 compared to Q4 2023, attributed to a reduction in headcount and discretionary payroll costs.
The company has engaged Priya Healthcare to assist with reimbursement services, which is expected to enhance market access and accelerate revenue growth in 2025.
Ekso Bionics Holdings Inc (EKSO) has established a strategic partnership with National Seating and Mobility to expand distribution of the Indigo personal device in the complex rehabilitation technology industry.

Negative

Revenue for the full year 2024 was $17.9 million, a slight decline from $18.3 million in 2023, attributed to the absence of procurement cycles with large delivery networks.
Net loss for Q4 2024 was $3.4 million, slightly higher than the $3.2 million loss in Q4 2023.
The company faced challenges in submitting Medicare claims, with only one claim reimbursed by July 2024 and subsequent claims still in the appeals process.
Ekso Bionics Holdings Inc (EKSO) anticipates that the go-to-market program for the Indigo personal device will take time to scale and produce results.
The company is still in the early stages of engaging with private insurance payers, focusing primarily on Medicare beneficiaries for the time being.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EKSO.OQ - Ekso Bionics Holdings Inc
Q4 2024 Ekso Bionics Holdings Inc Earnings Call
Mar 03, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings, and welcome to the Exobionics 4th quarter 2024 financial results conference call. At this time, all participants are in a listen-only mood. A question answer session will follow the full presentation.

If anyone should require operator assistance, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Steven Kilmer.

Thank you. We begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon, everyone.

Earlier today, Exo Bionics

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.